Answers are grounded in this paper and cite their sources.
Translating fine-grained intracellular dynamics into predictable systemic clinical phenotypes remains a core challenge in biomedical research. This review explores the architectural continuum and translational value of artificial intelligence (AI) virtual patients (AIVPs) for bridging the gap between microscale biological mechanisms and macroscale clinical manifestations. We clarify the computational hierarchy of AIVPs, covering AI-based virtual cells, AI-based virtual extracellular vesicles, and AI virtual organoids. These modules jointly form the mechanistic basis of the integrated AIVP models. This review also clearly distinguishes between the epistemological connotations of AIVPs and digital twins (DTs). AIVPs act as population-level synthetic archetypes optimized for in silico clinical trials, whereas DTs serve as individualized longitudinal replicas updated by real-world data assimilation. Focusing on pharmaceutical research and development and regulatory science, we discuss the capacity of AIVP cohorts to reduce developmental risks in drug research. These in silico models can be used to construct synthetic control arms, optimize dynamic precision dosing, and accelerate regulatory progress via Model-Informed Drug Development. We further summarize the key obstacles restricting the clinical translation of AIVPs, including epistemological limitations, inadequate infrastructure, and complex socio-regulatory constraints. Resolving data fragmentation, reducing algorithmic bias, and unifying verification and validation standards are critical for transforming AIVPs from theoretical prototypes into credible regulatory and clinical tools (Graphical Abstract).
No takes yet. Share an insight, caveat, or question.
Pei et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: